Menopause HRT online in 2026: which hormone, by which route, and what the label now says

01 / 06The warning that just changed, and the part of it that did not

For more than twenty years, menopausal hormone therapy carried a boxed warning that shaped how it was prescribed, how it was marketed, and how willing people were to consider it at all. That changed recently enough that a lot of what you will read online predates it.

The reasoning matters for anyone weighing this now. The warnings followed the Women's Health Initiative, a study whose participants averaged 63 years of age, more than a decade past the average age at menopause, using a hormone formulation no longer in common use. None of that makes hormone therapy right for any particular person. It does mean that the risk framing most of us absorbed was built on a population and a product that may not resemble the decision in front of you.

What this does not change is the endometrial point, and that is precisely where route and regimen do their work. It is the reason a prescriber pairs estrogen with progesterone for someone with a uterus, and the reason the service you choose should be asking about that before it sells you anything.

02 / 06Ten routes, and why the choice is not cosmetic

Estradiol is not one product. Across approved applications in Drugs@FDA it exists as a tablet, a capsule, a chewable tablet, a cream, a metered gel, a transdermal spray, a patch system, a vaginal insert, an extended-release film and an injectable, across 484 approved products. The route is the main axis on which these services actually differ, and it is not a styling preference.

A service that offers you one route is not necessarily worse than one that offers four, but it is offering you a narrower conversation. That is the single most useful thing to notice when comparing them, and it is what the table below is organised around.

03 / 06The four, on hormone and route

Everything below was read from each provider's own pages on 17 September 2026. Where a service does not publish a price, the cell says so.

The clearest split is not clinical, it is commercial. Alloy is built as a cash-pay catalogue and publishes the widest set of routes. Midi and Gennev are built around insurance and publish far less about specific products, because with them the product is decided in the consultation. Neither approach is better in the abstract. They suit different people, and knowing which one you are looking at saves a wasted appointment.

04 / 06One ingredient on this page is not an approved drug at all

Two of these services list a facial cream containing estriol, a third estrogen distinct from the estradiol everything else here is built on. It is worth knowing exactly where estriol sits, and we checked rather than assumed.

This matters more here than it would elsewhere, because the rest of the category is unusually well served by approved products. When a service can prescribe an approved patch, an approved gel, an approved spray and an approved vaginal cream, a compounded item sitting alongside them deserves to be labelled as what it is.

05 / 06Insurance or cash, and what that actually decides

The payment model is not just a billing detail in this category, because it changes what gets discussed. An insurance-billed service has a clinician deciding the product with you and a formulary shaping the options. A cash-pay catalogue puts the route in front of you first and the consultation second.

Midi states plainly that it is insurance-covered and staffed by women's health specialists, and its published care plans read like clinical bundles rather than product lists: an HRT patch with vaginal estrogen and hormone testing, or estradiol cream with progesterone and a thyroid panel, or bone density screening. Gennev likewise states it is covered by insurance companies. Evernow sits in between, running a membership from $35 a month while also offering an insurance-eligible one-off virtual visit with a menopause clinician, no membership required. Alloy is explicit that it is cash-pay and takes FSA and HSA cards.

If you have coverage, the insurance-billed route will usually cost less and the generic estradiol underneath it is inexpensive either way. Our wider guide to getting a prescription without insurance covers the arithmetic when you do not.

06 / 06Method, and what we did not do

We read each provider's own published pages on 17 September 2026 and recorded the hormones and routes each lists and what it says about payment. Where a service does not publish a price or does not itemise products, the table says so rather than carrying our inference. Gennev in particular is described thinly here because it publishes thinly, not because it offers little.

We did not enrol in any of these services, attend a consultation, or obtain any prescription. Nothing on this page is medical advice, and no part of it should be read as a recommendation that hormone therapy is or is not right for you. Whether to start, which route, and with what regimen are decisions for a clinician who knows your history, particularly given the endometrial point in section one.

The regulatory facts are reproducible. The approved dosage forms, the 484 estradiol products, the Evamist application number and the zero result for estriol all come from Drugs@FDA, and the estriol query was run alongside the estradiol query as a control so that the zero means something. The labeling change comes from the FDA's own announcements, linked below.

Estradiol is old enough and cheap enough that state prescription assistance programmes often cover it outright, and Health Britannica carries the clinical background on each route.